Percentage of participants with complete response, defined as no emesis (vomiting or retching) and no need for rescue therapy (indicated if vomiting/retching and/or nausea score ≥4 or upon participant's request) were reported. The severity of nausea was scored using a self-reported, 11-point numerical Verbal Rating Scale (VRS), where 0 represents no nausea and 10 represents the worst nausea possible. Significant nausea was defined as a VRS score ≥4. Percentages are rounded off to whole number at the nearest single decimal.

FAS included all participants who were randomized to treatment and received both doses of double-blind study drug before and during surgery.

Percentage of participants with complete response, defined as no emesis (vomiting or retching) and no need for rescue therapy (indicated if vomiting/retching and/or nausea score ≥4 or upon participant's request) were reported. The severity of nausea was scored using a self-reported, 11-point numerical Verbal Rating Scale (VRS), where 0 represents no nausea and 10 represents the worst nausea possible. Significant nausea was defined as a VRS score ≥4. Percentages are rounded off to whole number at the nearest single decimal.

FAS included all participants who were randomized to treatment and received both doses of double-blind study drug before and during surgery.

Percentage of participants with emesis, defined as vomiting (the forceful discharge of even the smallest amount of stomach contents) or retching (the same muscular movements as vomiting but without expulsion of stomach contents) were reported. Percentages are rounded off to whole number at the nearest single decimal.

FAS included all participants who were randomized to treatment and received both doses of double-blind study drug before and during surgery.

Percentage of participants with emesis, defined as vomiting (the forceful discharge of even the smallest amount of stomach contents) or retching (the same muscular movements as vomiting but without expulsion of stomach contents) were reported. Percentages are rounded off to whole number at the nearest single decimal.

FAS included all participants who were randomized to treatment and received both doses of double-blind study drug before and during surgery.

Percentage of participants without nausea, defined as urge to vomit without the presence of expulsive muscular movements were reported. Percentages are rounded off to whole number at the nearest single decimal.

FAS included all participants who were randomized to treatment and received both doses of double-blind study drug before and during surgery.

Percentage of participants without nausea, defined as urge to vomit without the presence of expulsive muscular movements were reported. CMH method was used for analysis. Percentages are rounded off to whole number at the nearest single decimal.

FAS included all participants who were randomized to treatment and received both doses of double-blind study drug before and during surgery.

Percentage of participants to whom rescue therapy was given as per local standard of care guidelines were reported. Percentages are rounded off to whole number at the nearest single decimal.

FAS included all participants who were randomized to treatment and received both doses of double-blind study drug before and during surgery.

Duration between end of wound closure to first emetic event i.e., vomiting or retching was reported. If a participant did not have an emetic event within 24 hours post-surgery, they were censored at 24 hours post-surgery. Cox proportional hazard model was used for analysis.

FAS included all participants who were randomized to treatment and received both doses of double-blind study drug before and during surgery. Overall number analyzed are the number of participants with events.

VRS was used to score postoperative nausea on 11-point numerical scale. The score ranges from 0-10, where 0 represents 'no nausea' and 10 represents 'worst nausea possible'. Higher score represents worsening of disease. Mixed-effects model for repeated measures (MMRM) was used for analysis. Least square mean (LSM) estimates extracted from MMRM are presented in the data table for each time point.

FAS included all participants who were randomized to treatment and received both doses of double-blind study drug before and during surgery. Overall number of participants analyzed are the participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at the specified time point.

Percentage of participants with total response, defined as no emesis, no nausea (VRS score <1), and no need for rescue therapy were reported. VRS was used to score postoperative nausea on 11-point numerical scale, where 0 represents 'no nausea' and 10 represents 'worst nausea possible'. Percentages are rounded off to whole number at the nearest single decimal.

FAS included all participants who were randomized to treatment and received both doses of double-blind study drug before and during surgery.

PK Set included all participants who received study drug and had at least 1 evaluable PK sample. Overall number analyzed is the number of participants with data available for analyses. Number analyzed is the number of participants with data available for analysis at the specified timepoint. The data for this outcome measure was collected and reported separately for the participants who received the unintended mis-dose of TAK-951 redacted mg.

An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an AE with an onset that occurs after receiving study drug. Percentages are rounded off to whole number at the nearest single decimal.

Safety Analysis Set (SAF) included all participants who were randomized to treatment and received both doses of double-blind study drug. The data for this outcome measure was collected and reported separately for the participants who received the unintended mis-dose of TAK-951 redacted mg.

Vital signs included heart rate, respiratory rate, systolic blood pressure (SBP) and diastolic blood pressure (DBP), body temperature and BMI. Percentage of participants with markedly abnormal vital sign values were reported. Percentages are rounded off to whole number at the nearest single decimal. Only categories with at least 1 participant with data are reported.

SAF included all participants who were randomized to treatment and received both doses of double-blind study drug. The data for this outcome measure was collected and reported separately for the participants who received the unintended mis-dose of TAK-951 redacted mg.

Percentage of participants with clinically significant ECG interpretation were reported. Percentages are rounded off to whole number at the nearest single decimal. A combined ECG interpretation was derived using ECG heart rate, PR interval, RR interval, QRS duration, QT interval, and QT interval with Fridericia correction method (QTcF).

SAF included all participants who were randomized to treatment and received both doses of double-blind study drug. The data for this outcome measure was collected and reported separately for the participants who received the unintended mis-dose of TAK-951 redacted mg. Overall number analyzed is the number of participants with data available for analyses. Clinical significance is based on PI determination.

Laboratory parameters included hematology and serum chemistry. Percentage of participants with markedly abnormal clinical laboratory values were reported. Percentages are rounded off to whole number at the nearest single decimal. Only categories with at least 1 participant with data are reported.

SAF included all participants who were randomized to treatment and received both doses of double-blind study drug. Number analyzed is the number of participants with data available for analysis for the specified category. The data for this outcome measure was collected and reported separately for the participants who received the unintended mis-dose of TAK-951 redacted mg.

Percentage of participants with ADA results as: ADA negative, ADA positive were reported. Participants with ADA positive status are defined as those who had confirmed positive ADA status in baseline or at least 1 postbaseline assessments. Participants with ADA negative status are defined as those who did not have positive ADA response at baseline and in all postbaseline assessments.

Immunogenicity Set included all participants who received at least 1 dose of study drug, had an ADA status assessment at baseline, and at least 1 postbaseline sample. Overall number analyzed is the number of participants with non-missing data for this outcome measure i.e., responders. The data for this outcome measure was collected and reported separately for the participants who received the unintended mis-dose of TAK-951 redacted mg.